Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brianna Quinley

Nurse Practitioner Salina, KS Nurse Practitioner

NPI 1346732336 CMS profile 4326936

828 Elmhurst Blvd, Salina, KS 67401

Open in the dashboard

General payments

$6,095

320 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brianna Quinley of Salina, KS is reported in the CMS Open Payments database as having received $6,095 across 320 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,363 76
2024 General $1,357 58
2023 General $966 55
2022 General $1,623 79
2021 General $786 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brianna Quinley
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Brianna Quinley were reported at $1,363. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Brianna Quinley Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $786 $135 $40–$426 $132
2022 $1,623 $152 $48–$470 $149
2023 $966 $166 $54–$529 $160
2024 $1,357 $173 $55–$556 $164
2025 $1,363 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,423 91 payments
  2. Sun Pharmaceutical Industries Inc. $846 31 payments
  3. Novartis Pharmaceuticals Corporation $784 37 payments
  4. Janssen Biotech, Inc. $706 34 payments
  5. E.R. Squibb & Sons, L.L.C. $577 36 payments
  6. Lilly USA, LLC $479 29 payments
  7. Amgen Inc. $194 10 payments
  8. Incyte Corporation $145 5 payments
  9. Regeneron Healthcare Solutions, Inc. $126 3 payments
  10. LEO Pharma Inc. $124 7 payments
  11. Other $689 37 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,709 315 payments
  2. Education $386 5 payments
Products named General payments · program years 2021–2025
  1. SKYRIZI $703 47 payments
  2. TREMFYA $633 29 payments
  3. SOTYKTU $577 36 payments
  4. TALTZ $460 28 payments
  5. COSENTYX $455 18 payments
  6. BLU-U $385 17 payments
  7. HUMIRA $313 20 payments
  8. RINVOQ $280 14 payments
  9. OLUMIANT $269 18 payments
  10. Otezla $194 10 payments
  11. Other $2,377 130 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

696

Median for Nurse Practitioner: 389

Drug cost

$944,889

Median for Nurse Practitioner: $21,885

Branded share of claims

14.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 15 $312,105
Humira(Cf) Pen Adalimumab Brand 19 $297,961
Cosentyx Sensoready (2 Pens) Secukinumab Brand 16 $122,903
Sotyktu Deucravacitinib Brand 11 $70,488
Otezla Apremilast Brand 12 $68,325
Dupixent Pen Dupilumab Brand 16 $59,872
Metronidazole Generic 35 $2,271
Clobetasol Propionate Generic 47 $2,026
Doxycycline Hyclate Generic 75 $1,880
Betamethasone Valerate Generic 61 $1,606

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$159,549

Of which drugs: $712

Medicare patients

1,337

Average age 75

Services billed

5,775

865 women, 472 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 42%
Diabetes 22%
Depression 17%
Osteoporosis 17%
Ischemic heart disease 16%
Atrial fibrillation 15%
Chronic kidney disease 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 53 101 $68

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $254
$254 11 —
COSENTYX
  • Novartis Pharmaceuticals Corporation $238
$238 16 —
SKYRIZI
  • AbbVie, Inc. $164
$164 15 —
RINVOQ
  • AbbVie, Inc. $71
$71 — —
SPEVIGO
  • Boehringer Ingelheim Pharmaceuticals, Inc. $67
$67 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

320 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record